Sunday's vote in Switzerland has raised fears that the measure is the latest in a long list of reforms that could curb the country's business-friendly environment.» Read More
*Q4 core earnings 30.1 pence vs consensus 30.2 p. LONDON, Feb 5- GlaxoSmithKline has predicted a pick-up in sales growth to around 2 percent this year as productivity in its drug research labs improves and pressure on sales in China moderates following a damaging bribery scandal.
Feb 3- Medical device maker Hologic Inc reported a better-than-expected adjusted quarterly profit as it sold more 3 D systems that help detect breast cancer, and its CEO said he would pursue the strategic review started by his predecessor.
*Pfizer to discuss favorable data with FDA. Feb 3- Pfizer Inc's experimental breast cancer drug significantly delayed progression of symptoms in a mid-stage trial, meeting the study's primary goal and keeping Pfizer in the forefront of a race for a new standard of care for the disease.
Feb 3- Pfizer Inc's experimental breast cancer drug significantly improved patient survival rates in a mid-stage trial without their condition worsening, maintaining the company's lead in the race for a new treatment standard for the disease.
*2013 sales rise 3 pct to 46.78 billion Sfr. BASEL, Jan 30- Roche offered shareholders a lower-than-expected dividend payout after reporting an 18 percent rise in full-year net profit, potentially a sign the Swiss pharmaceuticals group might be keeping its cash for deals.
*Novartis CEO pay flat at 13.2 mln Sfr. BASEL, Jan 29- Novartis kept pay for its Chief Executive Joe Jimenez steady, after cutting it last year before a Swiss vote to force companies to accept shareholder limits on executive rewards.
BASEL, Jan 29- Novartis is looking at options, such as joint ventures, for three smaller businesses to bring them in line with its world-leading pharmaceutical operations, it said on Wednesday, in a review due to be completed by the end of summer.
Jan 28- Pfizer Inc reported better-than-expected fourth-quarter results, helped by higher sales of drugs for cancer, nerve pain and arthritis, and forecast 2014 earnings in line with Wall Street estimates.
Veterans of the annual World Economic Forum in Davos seized on the wobble as a warning that expectations for a smooth upswing were misplaced, and that recovery would likely be volatile and uneven. "I hear way too much optimism now," Larry Fink, CEO of investment group BlackRock, told the forum.
FRANKFURT, Jan 24- Hedge fund Elliott has called an end to its fight with McKesson over the drugs distributor's acquisition of German peer Celesio, selling its shares and vowing not to disrupt the deal further, a source familiar with the transaction said.
*Knocks back Teva's Nerventra and Novartis' serelaxin. LONDON, Jan 24- Europe's drugs regulator gave its backing on Friday for marketing approval to be granted for Bayer's pulmonary hypertension drug Adempas and for GlaxoSmithKline's diabetes medicine Eperzan.
FRANKFURT, Jan 24- Shares in Celesio jumped to their highest in more than three and a half years on Friday after U.S. drugs distributor McKesson succeeded in its renewed attempt to gain control of its German peer.
WASHINGTON/ MUMBAI, Jan 23- Indian drugmaker Ranbaxy Laboratories Ltd faces long delays and high costs in launching big-selling generic drugs in the United States after products from a fourth plant were banned from entering its main market due to manufacturing violations.
*McKesson say to enter into domination agreement with Celesio. FRANKFURT, Jan 23- U.S. drugs distributor McKesson succeeded in its second attempt to win control of German peer Celesio in a deal with Celesio's two largest shareholders, German investment group Haniel and U.S. hedge fund Elliott.
FRANKFURT, Jan 23- The majority shareholder behind German drugs distributor Celesio is in talks to hammer out a deal that could salvage its on-off takeover by U.S. peer McKesson, three people familiar with the negotiations said.
We are going to see health care as a growth industry well into the future, says Joe Jimenez, Novartis CEO, sharing his thoughts on elevating the economic potential of a healthier population.
*Analysts had forecast annual sales of $407 mln by 2017. ZURICH, Jan 21- An experimental Roche drug designed to treat the "negative symptoms" of schizophrenia failed to meet its main goal in two late-stage studies, dealing a blow to the Swiss drugmaker's research hopes in the risky area of brain science.
*Drug firms may threaten to cut South Africa investment. JOHANNESBURG, Jan 17- South Africa on Friday slammed global drug firms over a covert campaign against its planned overhaul of intellectual property laws to favour cheaper generic drugs, accusing pharmaceutical companies of a "satanic" plot to commit "genocide".
JOHANNESBURG, Jan 17- Global drug firms may threaten to cut their South African investments as part of a campaign against Pretoria's plans to overhaul its intellectual property laws to favour generic production, documents seen by Reuters show.
FRANKFURT, Jan 9- U.S. drugs wholesaler McKesson raised its offer for German peer Celesio to about 6.2 billion euros including debt, mollifying an activist hedge fund that had been blocking the deal. McKesson increased its bid to 23.50 euros per Celesio share from the 23 euros it offered in October, the San Francisco- based company said on Thursday.